Xceleron

Xceleron, founded in 1997 in York, UK, and now based in Germantown, Maryland, specializes in bioanalytical accelerator mass spectrometry (AMS) services to enhance drug development. The company pioneered techniques for human microdosing and microtracing, focusing on the pharmacokinetics and metabolism of developmental drugs during early clinical trial phases. Xceleron's services include micro-dosing, preclinical evaluation, intravenous pharmacokinetics, metabolite profiling, and mass balance investigations in humans. Their expertise is particularly valuable given the complexity of modern small molecules, which often exhibit low solubility and lengthy half-lives, necessitating early pharmacokinetic characterization to improve the cost-effectiveness of clinical development. Through a commitment to integrity and collaboration, Xceleron aims to accelerate the delivery of life-changing products to the market.